SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-23-008144
Filing Date
2023-11-14
Accepted
2023-11-14 17:19:32
Documents
39
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT cns_i10q-093023.htm   iXBRL 10-Q 473329
2 CERTIFICATION cns_ex3101.htm EX-31.1 6721
3 CERTIFICATION cns_ex3102.htm EX-31.2 6767
4 CERTIFICATION cns_ex3201.htm EX-32.1 3100
5 CERTIFICATION cns_ex3202.htm EX-32.2 3093
  Complete submission text file 0001683168-23-008144.txt   2742358

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnsp-20230930.xsd EX-101.SCH 19258
7 XBRL CALCULATION FILE cnsp-20230930_cal.xml EX-101.CAL 25143
8 XBRL DEFINITION FILE cnsp-20230930_def.xml EX-101.DEF 108410
9 XBRL LABEL FILE cnsp-20230930_lab.xml EX-101.LAB 209218
10 XBRL PRESENTATION FILE cnsp-20230930_pre.xml EX-101.PRE 176185
33 EXTRACTED XBRL INSTANCE DOCUMENT cns_i10q-093023_htm.xml XML 279172
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39126 | Film No.: 231408006
SIC: 2834 Pharmaceutical Preparations